S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:GANX

Gain Therapeutics (GANX) Stock Price, News & Analysis

$3.77
+0.04 (+1.07%)
(As of 03/28/2024 ET)
Today's Range
$3.68
$3.95
50-Day Range
$3.27
$5.04
52-Week Range
$2.00
$6.19
Volume
102,211 shs
Average Volume
152,390 shs
Market Capitalization
$61.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.33

Gain Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
121.0% Upside
$8.33 Price Target
Short Interest
Healthy
0.88% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.71mentions of Gain Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.18) to ($1.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.11 out of 5 stars

Medical Sector

600th out of 938 stocks

Pharmaceutical Preparations Industry

284th out of 437 stocks

GANX stock logo

About Gain Therapeutics Stock (NASDAQ:GANX)

Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

GANX Stock Price History

GANX Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Gain Therapeutics (NASDAQ:GANX) Shares Down 10.1%
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
GANX Mar 2024 7.500 call
Amgen 4Q Revenue Surges as Acquisition Boosts Results
GANX Gain Therapeutics, Inc.
See More Headlines
Receive GANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/29/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GANX
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.33
High Stock Price Target
$10.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+121.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-17,590,000.00
Pretax Margin
-40,138.18%

Debt

Sales & Book Value

Annual Sales
$50,000.00
Book Value
$1.59 per share

Miscellaneous

Free Float
11,490,000
Market Cap
$48.67 million
Optionable
Optionable
Beta
0.47
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

GANX Stock Analysis - Frequently Asked Questions

Should I buy or sell Gain Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gain Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GANX shares.
View GANX analyst ratings
or view top-rated stocks.

What is Gain Therapeutics' stock price target for 2024?

3 brokerages have issued twelve-month price targets for Gain Therapeutics' stock. Their GANX share price targets range from $6.00 to $10.00. On average, they predict the company's share price to reach $8.33 in the next twelve months. This suggests a possible upside of 121.0% from the stock's current price.
View analysts price targets for GANX
or view top-rated stocks among Wall Street analysts.

How have GANX shares performed in 2024?

Gain Therapeutics' stock was trading at $3.27 at the beginning of 2024. Since then, GANX shares have increased by 15.3% and is now trading at $3.77.
View the best growth stocks for 2024 here
.

Are investors shorting Gain Therapeutics?

Gain Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 156,700 shares, an increase of 16.4% from the February 29th total of 134,600 shares. Based on an average daily trading volume, of 171,900 shares, the short-interest ratio is presently 0.9 days. Currently, 0.9% of the company's stock are sold short.
View Gain Therapeutics' Short Interest
.

When is Gain Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our GANX earnings forecast
.

How were Gain Therapeutics' earnings last quarter?

Gain Therapeutics, Inc. (NASDAQ:GANX) released its quarterly earnings data on Friday, November, 12th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.03. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.04 million.

When did Gain Therapeutics IPO?

Gain Therapeutics (GANX) raised $40 million in an initial public offering (IPO) on Thursday, March 18th 2021. The company issued 3,600,000 shares at $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager.

Who are Gain Therapeutics' major shareholders?

Gain Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Royal Bank of Canada (1.55%), Vanguard Group Inc. (0.68%), Vanguard Group Inc. (0.68%), Northern Trust Corp (0.34%), Raymond James & Associates (0.18%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Eric I Richman and Matthias Alder.
View institutional ownership trends
.

How do I buy shares of Gain Therapeutics?

Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GANX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners